The JI PBL Intereron Source
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Patterson, S.
Right arrow Articles by Karadimitris, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Patterson, S.
Right arrow Articles by Karadimitris, A.
The Journal of Immunology, 2005, 175: 5087-5094.
Copyright © 2005 by The American Association of Immunologists

Human Invariant NKT Cells Are Required for Effective In Vitro Alloresponses1

Scott Patterson*, Ioannis Kotsianidis*, Antonio Almeida*, Marianna Politou*, Amin Rahemtulla*, Bini Matthew{dagger}, Richard R. Schmidt{dagger}, Vincenzo Cerundolo{ddagger}, Irene A. G. Roberts* and Anastasios Karadimitris2,*

* Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom; {dagger} Department of Chemistry, University of Konstanz, Konstanz, Germany; and {ddagger} Tumour Immunology Unit, Weatherall Institute of Molecular Medicine, Oxford, United Kingdom

NKT cells are a small subset of regulatory T cells conserved in humans and mice. In humans they express the V{alpha}24J{alpha}18 invariant chain (hence invariant NKT (iNKT) cells) and are restricted by the glycolipid-presenting molecule CD1d. In mice, iNKT cells may enhance or inhibit anti-infectious and antitumor T cell responses but suppress autoimmune and alloreactive responses. We postulated that iNKT cells might also modulate human alloreactive responses. Using MLR assays we demonstrate that in the presence of the CD1d-presented glycolipid {alpha}-galactosylceramide ({alpha}GC) alloreactivity is enhanced (37 ± 12%; p < 0.001) in an iNKT cell-dependent manner. iNKT cells are activated early during the course of the MLR, presumably by natural ligands. In MLR performed without exogenous ligands, depletion of iNKT cells significantly diminished the alloresponse in terms of proliferation (58.8 ± 24%; p < 0.001) and IFN-{gamma} secretion (43.2 ± 15.2%; p < 0.001). Importantly, adding back fresh iNKT cells restored the reactivity of iNKT cell-depleted MLR to near baseline levels. CD1d-blocking mAbs equally reduced the reactivity of the iNKT cell-replete and -depleted MLR compared with IgG control, indicating that the effect of iNKT cells in the in vitro alloresponse is CD1d-dependent. These findings suggest that human iNKT cells, although not essential for its development, can enhance the alloreactive response.




This article has been cited by other articles:


Home page
J. Immunol.Home page
S. Patterson, A. Chaidos, D. C. A. Neville, A. Poggi, T. D. Butters, I. A. G. Roberts, and A. Karadimitris
Human Invariant NKT Cells Display Alloreactivity Instructed by Invariant TCR-CD1d Interaction and Killer Ig Receptors
J. Immunol., September 1, 2008; 181(5): 3268 - 3276.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. Yamaura, C. Hotta, M. Nakazawa, L. Van Kaer, and M. Minami
Human invariant V{alpha}24+ natural killer T cells acquire regulatory functions by interacting with IL-10-treated dendritic cells
Blood, April 15, 2008; 111(8): 4254 - 4263.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J. W. Molling, J. A.E. Langius, J. A. Langendijk, C. R. Leemans, H. J. Bontkes, H. J.J. van der Vliet, B. M. E. von Blomberg, R. J. Scheper, and A. J.M. van den Eertwegh
Low Levels of Circulating Invariant Natural Killer T Cells Predict Poor Clinical Outcome in Patients With Head and Neck Squamous Cell Carcinoma
J. Clin. Oncol., March 1, 2007; 25(7): 862 - 868.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2005 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2005 by The American Association of Immunologists, Inc. All rights reserved.